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Novel topoisomerase I inhibitors are being developed as potential
therapeutic agents for a variety of solid tumours (de Souza et al,
1997). The topoisomerase I inhibitor camptothecin has been
shown to have substantial activity against a variety of prostate
cancer cell lines in vitro. Recently, 9-aminocamptothecin, a
derivative of camptothecin, has been shown to be active against
hormone-refractory prostate cancer cells, and it is being tested in a
phase II clinical trial (de Souza et al, 1997). Camptothecin has
been shown to induce single-strand DNA breaks in the presence of
topoisomerase I, which is the major target for its anti-tumour
effect (Hsiang et al, 1989).
The cell surface receptor Fas (CD95/APO-1) belongs to the
nerve growth factor/tumour necrosis factor (NGF/TNF) receptor
family, and its main function is believed to be the induction of
apoptosis in a variety of cell types (Yonehara et al, 1989; Oehm
et al, 1992). The Fas/FasL system plays a key role in the develop-
ment, homeostasis, modulation and function of the immune
system (Leibson, 1997). In addition, Fas has been implicated in the
maintenance of immune privilege in tissues such as the brain, eyes
and testis, presumably by inducing apoptosis in infiltrating inflam-
matory cells (Griffith et al, 1995). The concept of a ‘Fas counter-
attack’ has emerged as a possible mechanism used by tumours to
escape immune surveillance (O’Connell et al, 1996; Villunger
et al, 1997). Recently, it has been shown that the normal
epithelium, as well as locally invasive prostate cancers, have the
potential to undergo Fas-induced apoptosis, whereas metastatic
prostate cancers have a reduced susceptibility to Fas-mediated
apoptosis (Hedlund et al, 1998; Costa-Pereira and Cotter,
1999).
DNA-damaging agents and DNA-reactive chemicals are able to
induce several cellular responses, the most general one being
stabilization of p53 and subsequent G0/G1 cell cycle arrest (Kastan
et al, 1991; Kuerbitz et al, 1992). However, many cancers express
mutant p53. Thus, additional responses must be used by cytotoxic
agents to induce apoptosis. Some DNA-damaging agents also
induce the activation of stress-activated protein kinases, such as
the SAPK/JNK and/or p38MAPK cascades (Dhanasekaran and
Reddy, 1998; Sánchez-Perez et al, 1998). The SAPK/JNK-
signalling pathway, which is activated in response to a variety of
cytotoxic stresses, involves the sequential phosphorylation of
MEKK, MKK4 and/or MKK7, and SAPK/JNK (Kyriakis and
Avruch, 1996). MKK7 has been shown to be induced by pro-
inflammatory cytokines and by osmotic stress (Finch et al, 1997).
Interestingly, Fas-induced apoptosis in T-cells was shown to
involve MKK7-SAPK/JNK- and MKK6-p38MAPK-signalling
modules (Toyoshima et al, 1997). It appears that pro-inflammatory
cytokines preferentially activate MKK7, whereas other stresses
activate both MKK4 and MKK7 (Dhanasekaran and Reddy,
1998). Thus, MKK4 and MKK7 seem to be differentially regu-
lated and it raises an interesting possibility that different stimuli
recruit MKK4 and MKK7 based on their need to co-stimulate the
p38MAPK cascade or not. Phosphorylated and activated
SAPK/JNK translocates into the nucleus where it can phosphory-
late a number of transcription factors, such as c-Jun and ATF-2
(Gupta et al, 1995).
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Summary We have previously shown that the androgen-independent prostate cancer cells DU145, despite expressing Fas and FasL, were
resistant to anti-Fas-induced apoptosis, and that this resistance could be overcome by pretreating the cells with sublethal doses of
camptothecin. Here, we provide evidence that SAPK/JNK activity is required for camptothecin sensitization to anti-Fas-induced apoptosis.
Camptothecin, but not Fas ligation, was shown to activate SAPK/JNK in a time-dependent manner, and to induce c-Jun expression. The
effects were more prominent in cells treated with both camptothecin and anti-Fas. The expression levels of MKP-1, a phosphatase which
regulates SAPK/JNK and which has been implicated in prostate cancer resistance to apoptosis, remained unchanged. Inhibition of caspases
had no effect on the SAPK/JNK activation, suggesting that this activation is an upstream event in the Fas-signalling pathway, and is
independent of caspase activity. Antisense oligonucleotides targeted to JNK1 and JNK2 reversed the effect of camptothecin. These results
suggest that stress kinase activation can significantly influence the fate of androgen-independent prostate cancer cells following Fas receptor
ligation. © 2000 Cancer Research Campaign
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University College, IrelandThe importance of SAPK/JNK activity in Fas-signalling path-
ways is still controversial, with evidence for and against its
involvement (Goillot et al, 1997; Juo et al, 1997; Lenczowski et al,
1997). Although DU145 cells are resistant to anti-Fas-mediated
cytotoxicity, the cells retain the cellular components of the apop-
totic machinery necessary to undergo death triggered by Fas, as
the resistance can be overcome by pretreating the cells with
sublethal doses of camptothecin. This effect is independent of
receptor expression, as levels were the same in resistant and sensi-
tized cells (Costa-Pereira and Cotter, 1999). Other cytotoxic drugs
(e.g. topoisomerase II inhibitors, non-classical alkylating agents,
RNA transcription inhibitors) have also been shown to sensitize
DU145 cells, although to a lesser extent (Uslu et al, 1997; Costa-
Pereira and Cotter, 1999). Since different modes of action sensitize
DU145 cells to anti-Fas-induced apoptosis, a common ‘stress-
activated pathway’ is likely to be targeted. Here, we provide
evidence that camptothecin, but not anti-Fas, strongly and persis-
tently activated SAPK/JNK in DU145 cells. Furthermore, we
show that activation of SAPK/JNK, and induction of c-Jun expres-
sion correlate with apoptosis. Antisense oligonucleotides targeted
to JNK1 and JNK2 reversed camptothecin sensitization to anti-
Fas-mediated apoptosis, suggesting a key role for SAPK/JNK in 
Fas-mediated apoptotic cell death in DU145 cells.
MATERIALS AND METHODS
Cell lines and reagents
The metastatic prostate cancer cell line DU145 was obtained from
American Type Culture Collection (Rockville, MD, USA).
Primary antibodies used in this study were anti-Fas IgM, clone 
Ch-11 (Upstate Biotechnology, Waltham, MA, USA); anti-JNK1,
C-17 (Santa Cruz); anti-c-Jun/AP-1, Ab-1 (Oncogene Research
Products, MA, USA); and anti-b-actin (Sigma, Poole, UK). The
caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone (z-VAD) was purchased from Enzyme System Products
(Livermore, CA, USA). Cell culture reagents were purchased from
Gibco-BRL (Paisley, UK), protein gel electrophoresis reagents
from BioRad (Hertfordshire, UK) and the SAPK/JNK assay kit
from New England BioLabs (UK) Ltd. (Hertfordshire, UK).
The phosphorothioate oligonucleotides used in this study were
purchased from Genosys (UK). Cytotoxic drugs were from Sigma,
and all other reagents were obtained from BDH (Cork, Ireland).
Cell culture
Cells were cultured in RPMI-1640 medium containing 5% (v/v)
fetal calf serum, 2 mML -glutamine, supplemented with peni-
cillin–streptomycin (10 IU ml–1, 10 mg ml–1) and fungizone
amphotericin B (2.5 mg ml–1). Cells were grown at 37°C in a
humidified 5% carbon dioxide atmosphere and were routinely
subcultured every 4 days. Cell density and viability were assessed
by trypan blue exclusion, using a haemocytometer.
Fas-induced cell death
Cells were plated in 24-well plates and treatment with anti-Fas
IgM (200 ng ml–1) was carried out for 24 h. Whenever used, cyto-
toxic drugs (100 ng ml–1 camptothecin, 2.5 mg ml–1 anisomycin),
were added 5 min prior to anti-Fas IgM. z-VAD was added 5 min
prior the addition of cytotoxics.
Morphological analysis
Cells were harvested and cytospun onto slides. Cells were then
stained using the Rapi-Diff II kit (LanganBack, Ireland), which is
consists of a fixing solution (100% methanol), an acid dye which
stains the nucleus (Eosin Y, 0.1% w/v; formaldehyde phosphate
dibasic, 0.4% w/v; potassium phosphate monobasic, 0.5% w/v),
and a basic dye which stains the cytoplasm (methylene blue-poly-
chrom, 0.4% w/v; azure A, 0.4% w/v; sodium phosphate dibasic,
0.4% w/v; potassium phosphate monobasic, 0.5% w/v). Cell
morphology was assessed by light microscopy, using previously
defined criteria, such as membrane blebbing, cell shrinkage and
chromatin condensation (Wyllie et al, 1980).
Western blot
Whole cell lysates were prepared by solubilizing ~106 cells in
20 ml of RIPA buffer (50 mM Tris–HCl, pH 7.4; 150 mM sodium
chloride (NaCl); 1 mM EGTA; 0.25% v/v sodium deoxycholate;
1.0% v/v NP-40; 1 mM sodium orthovanadate; 1 mM sodium
fluoride; 0.1 mM phenylmethylsulphonyl fluoride; 1.0 mg ml–1
antipain; 1.0 mg ml–1 aprotinin; 1.0 mg ml –1 chymostatin;
0.1 mg ml–1 leupeptin; 4.0 mg ml–1 pepstatin) and incubating cells
on ice for 1 h. Prior to electrophoresis, cells were diluted in
2 ´ SDS (sodium dodecyl sulphate) gel-loading buffer (100 mM
Tris–HCl, pH 6.8; 200 mM dithiothreitol (DTT); 4.0% w/v SDS;
0.2% w/v bromophenol blue; 20% v/v glycerol) and boiled for 15
min. Proteins were separated in a 10% (w/v) polyacrylamide gel
and blotted onto Trans-Blot nitrocellulose membrane. After
blocking, the membrane was incubated with the primary antibody
of interest (anti-c-Jun, 2.5 mg ml–1; anti-SAPK/JNK, 1 mg ml–1) for
1 h at room temperature, followed by the relevant secondary
horseradish peroxidase (HRP)-conjugated antibody. The
membrane was probed with enhanced chemiluminescence (ECL)
(Amersham) and exposed to Kodak X-OMAT LS film (Sigma).
Measurement of SAPK/JNK activity
SAPK/JNK kinase activity was measured using a non-radioactive
kit (New England Biolabs) which employs an N-terminal c-Jun
fusion protein bound to glutathione sepharose beads to selectively
precipitate SAPK/JNK from cell lysates.
Preparation of cell lysates
DU145 (1´106) were plated in 6-well plates and cultured for 24 h.
Cells were treated with either camptothecin (100 ng ml–1), anti-Fas
IgM (200 ng ml–1), or both. At the appropriate times, after a wash
with cold phosphate buffered saline (PBS), 500 ml of 1 ´ lysis
buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 1 mM EGTA; 1 mM
EDTA; 1% v/v Triton X-100; 2.5 mM sodium pyrophosphate;
1m M b-glycerolphosphate; 1 mM Na3VO4; 1 mg ml–1 leupeptin;
1m M PMSF) was added to cells and the plate was incubated on ice
for 5 min. The cells were scraped off the plate, transferred to
microcentrifuge tubes and sonicated 4 times for 5 s. Cells were
then centrifuged at 14 000 rpm for 10 min at 4°C and the
supernatants were stored at –70°C.
SAPK/JNK ‘immunoprecipitation’
GSH-c-Jun fusion protein (2 mg) was added to protein sample
(250 mg) and incubated overnight at 4°C. Samples were
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Figure 1 Anisomycin causes an early and persistent activation of SAPK/JNK, and sensitiszes DU145 cells to anti-Fas in a manner analogous to camptothecin.
(A) SAPK/JNK activity is evident 1 h following treatment with anisomycin (2.5 mg ml–1), and remains elevated at least until 12 h post-treatment. As an additional
control for initial protein concentration, b-actin was assessed in supernatant extracts. (B) Cells were treated with camptothecin (100 ng ml–1), or anisomycin
(2.5 mg ml–1), and concomitantly incubated with anti-Fas IgM (200 ng ml–1), for 24 h, and apoptosis levels were assessed by morphological analysis. The data
(from three independent microscopic fields) represents mean apoptosis ± standard error of the mean. (C) Typical cellular morphology of (A) untreated DU145
cells, and cells treated with (B) anti-Fas IgM, (C) camptothecin, (D) camptothecin plus anti-Fas; (E) anisomycin; and (F) anisomycin plus anti-Fas. The results
shown are representative of at least three independent experiments
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Cmicrocentrifuged at 14 000 rpm for 1 min at 4°C. The pellets were
washed twice with 500 ml of 1 ´ lysis buffer, followed by two
washes with 500 ml of 1 ´ kinase buffer (25 mM Tris, pH 7.5; 5 mM
b-glycerolphosphate; 2 mM DTT; 0.1 mM Na3VO4; 10 mM
magnesium chloride (MgCl2)).
Kinase assay
The pellet was then resuspended in 50 ml 1 ´ kinase buffer supple-
mented with 240 mM ATP and incubated for 30 min at 30°C.
The reaction was terminated with 25 ml 3 ´ SDS sample buffer
(187.5 mM Tris–HCl, pH 6.8; 6% w/v SDS; 30% v/v glycerol;
150 mM DTT, 0.3% w/v bromophenol blue). Samples were boiled
for 5 min and then microcentrifuged for 2 min. Samples were then
run on a 10% (w/v) SDS polyacrylamide gel.
Western immunoblotting and detection of proteins
The membrane was blocked with blocking buffer (1 ´ TBS; 0.1%
Tween-20; 5% w/v non-fat dry milk) for 1 h at room temperature,
and then incubated with a phospho-specific-c-Jun antibody
(1/1000 dilution in 1 ´ TBS, 0.05% v/v Tween-20; 5% w/v BSA)
at 4°C, overnight. The membrane was incubated with anti-rabbit-
HRP-conjugated antibody (1/2000) for 1 h, at room temperature,
and probed with Phototope®-HRP Western blot detection kit (New
England BioLabs) before exposure to Kodak X-OMAT LS film
(Sigma).
Inhibition of SAPK/JNK activity by antisense
olinucleotides
The antisense (AS) sequences were chosen based on their ability
to eliminate steady target RNA > 95% (Bost et al, 1997). Two
antisense sequences against the two major forms of SAPK/
JNK (JNK1 and JNK2) were chosen with sequences 5¢-CT-
CTCTGTAGGCCCGC TTGG-3¢ and 5¢-GTCCGGGCCAGGCC-
AAAGTC-3¢. The sequences of the control (NS) oligonucleotides
were 5¢-CTTTCCGTTGGACCCCTGGG-3¢ and 5¢-GTGCGCG-
GAGCCCGAAATC-3¢. Cells were harvested by trypsinization,
washed twice with warm PBS, then resuspended in electropora-
tion buffer (control samples, PBS only; AS-treated samples, PBS
containing 2 mM JNK1 AS and 2 mM JNK2 AS; NS-treated
samples, PBS containing 2 mM JNK1 NS and 2 mM JNK2 NS) at
1 ´ 106/0.8 ml, and incubated at room temperature for 10 min. The
oligonucleotides were delivered by electroporation (0.15 mV,
960 mF) using a Gene Pulser (BioRad). Following incubation on
ice for 14 min, cells were washed twice with cold PBS,
resuspended in complete media (RPMI-1640; FCS, 5% v/v; L-
Gln,\ 2 mM), supplemented with antibiotics. Cells were then
plated in 6-well plates and cultured for 24 h, after which period
treatments with anti-Fas (200 ng ml–1) and camptothecin (100 ng
ml–1) were carried out. At the appropriate times, protein extracts
and cytospins were prepared, and analysed as previously
described.
RESULTS
Anisomycin potentiates anti-Fas-mediated cytotoxicity
in a manner analogous to camptothecin
Anisomycin has previously been shown to act exactly like a
signalling agonist in eliciting highly specific and virtually complete
homologous desensitization of immediate early (IE) gene induction
and stress kinase activation (Hazzalin et al, 1998). Indeed, in DU145
prostate cancer cells anisomycin induces an early and persistent acti-
vation of SAPK/JNK (Figure 1A). There is some controversy in the
literature as to whether or not SAPK/JNK activity can influence
Fas-induced apoptotic signalling pathways. We have recently shown
that DU145 cells were highly resistant to anti-Fas IgM treatment.
This resistance was overcome by pretreating the cells with sublethal
doses of camptothecin. To address the question of whether camp-
tothecin was sensitizing DU145 cells to anti-Fas via a mechanism
which involved activation of SAPK/JNK, we elevated the activity of
SAPK/JNK using anisomycin and assessed cell sensitivity to Fas
ligation. Cells were treated for 24 h with equally sublethal doses of
anisomycin (2.5 mg ml–1) and anti-Fas (200 ng ml–1), and apoptosis
levels were compared with those induced by concomitant treatment
of cells with camptothecin (100 ng ml–1) and anti-Fas IgM. Figure
1B and IC shows that anisomycin potentiated anti-Fas-induced
apoptosis to exactly the same extent as camptothecin, suggesting
that elevation of SAPK/JNK activity can sensitize DU145 prostate
cancer cells to anti-Fas-induced apoptosis. Anisomycin has been
reported to activate both SAPK/JNK and p38MAPK. We repeated
our Fas sensitization experiments in the presence of a specific
p38MAPK inhibitor SB203580 (Juo et al, 1997). Inhibition of this
kinase had no effect on sensitization to Fas-mediated apoptosis (data
not shown).
Camptothecin, but not anti-Fas, strongly and
persistently activates SAPK/JNK in DU145 cells
To address the question of whether camptothecin was sensitizing
the DU145 cells to anti-Fas by activating the SAPK/JNK cascade,
cells were treated with anti-Fas (200 ng ml–1), camptothecin
(100 ng ml–1), or both, for varying periods of time, and the kinase
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Figure 2 Camptothecin, but not anti-Fas, strongly and persistently activates
SAPK/JNK in DU145 prostate cancer cells. (A) SAPK/JNK activity was
measured on extracts of untreated cells (lanes 1 and 5), and of cells treated
with anti-Fas (200 ng ml–1) (lanes 2 and 6), camptothecin (100 ng ml–1) (lanes
3 and 7), or both (lanes 4 and 8) for 1 (lanes 1–4), or 8 h (lanes 5–8).
SAPK/JNK activity is evident 1 h after treatment with camptothecin and anti-
Fas, and it increases in a time-dependent manner. Although anti-Fas fails to
activate SAPK/JNK, it potentiates camptothecin-induced SAPK/JNK activity.
(B) Endogenous expression of SAPK/JNK is not altered by treatment with
camptothecin, anti-Fas, or bothactivity was measured as described in Materials and Methods.
Camptothecin strongly and persistently activated SAPK/JNK
(Figure 2A). Anti-Fas treatment alone failed to induce SAPK/JNK,
but it potentiated the activation induced by camptothecin. The
endogenous levels of SAPK/JNK (Figure 2B) remained
unchanged, indicating that camptothecin and anti-Fas have no
effect on SAPK/JNK expression levels.
Expression of c-Jun is induced by camptothecin, but
not by anti-Fas
c-Jun is an inducible transcription factor which directs changes of
gene expression in response to multiple extracellular stimuli.
Transcription of c-jun mRNA rises after exposure to cytokines and
cytotoxic stresses (Ham et al, 1995; Leppä et al, 1998). However,
the activity of c-Jun can also be modulated at the protein level.
Indeed, a number of regulatory phosphorylations occur on Ser63
and Ser73, and Thr91 and/or Thr93 within the trans-activation
domain of c-Jun. These phosphorylations result in the stabilization
of c-Jun, as well as enhanced trans-activation and DNA-binding
activity (Smeal et al, 1992; Lëppa et al, 1998). Importantly, c-Jun
has been shown to be activated during the initiation of apoptosis
induced by radiation and chemotherapy in the prostate (Furuya and
Isaacs, 1993). Here, we show that treatment with camptothecin,
but not with anti-Fas, induced c-Jun expression (Figure 3),
providing further evidence for an important role of SAPK/JNK
cascade in camptothecin-mediated anti-Fas-induced apoptosis in
prostate cancer cells.
Expression of MKP-1 remains unchanged following
treatment with camptothecin and anti-Fas
The mitogen-activated protein kinase phosphatase 1 (MKP-1) is
induced by several oncogenes in the Ras-dependent pathway and it
can inactivate both the MAPK (ERK1/ERK2), and the SAPK/JNK
pathways (Magi-Galluzzi et al, 1997). In addition, it has been
shown that MKP-1 is often overexpressed in prostate cancers and
that it inhibits apoptosis in human prostate tumours (Magi-
Galluzzi et al, 1997). Moreover, SAPK/JNK enzymatic activity
seems to be inversely related to MKP-1 expression (Magi-Galluzzi
et al, 1998). To determine whether camptothecin sensitization was
mediated via inhibition or down-regulation of MKP-1, cells were
treated as described above and the expression of MKP-1 assessed
by Western blot analysis (Figure 4). Neither camptothecin, nor
anti-Fas had any effect on MKP-1 expression, indicating that
camptothecin’s effect was independent of MKP-1 expression
levels.
Camptothecin-induced activation of SAPK/JNK is an
upstream event in the Fas-signalling pathway
Fas signalling has been shown to involve sequential activation of
caspases (Enari et al, 1996; Logthorne et al, 1997). We have previ-
ously shown that camptothecin and anti-Fas-induced apoptosis
involved caspases, as apoptosis could be blocked by the caspase
pan-inhibitor z-VAD (Costa-Pereira and Cotter, 1999). To investi-
gate whether inhibition of caspase activity influenced campto-
thecin-induced SAPK/JNK activation, cells were treated with
camptothecin (100 ng ml–1), and anti-Fas (200 ng ml–1) in the
presence of z-VAD (50 mM) and the activity of SAPK/JNK was
determined as previously. Although z-VAD completely blocked
anti-Fas-mediated cytotoxicity, it had no effect on camptothecin-
induced SAPK/JNK activity (Figure 5). These results suggest that
SAPK/JNK activation is not caspase-dependent, and that
SAPK/JNK activation is not a secondary effect of the death
induced by anti-Fas. Furthermore, the results indicate that
camptothecin-induced activation of SAPK/JNK is upstream from
caspases and, thus an early event in the Fas-signalling pathway.
SAPK/JNK activity is absolutely required for the
induction of apoptosis in DU145 cells by camptothecin
and anti-Fas
Experiments thus far have demonstrated that the induction of
stress kinase activity parallels camptothecin sensitization of
DU145 cells to anti-Fas-induced apoptosis. Moreover, the induc-
tion of SAPK/JNK by anisomycin mimicked the effects mediated
by camptothecin. In order to establish whether SAPK/JNK activity
is specifically required for the sensitization to Fas-mediated apop-
tosis we have used phosphorothioate antisense oligonucleotides
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Figure 3 The c-Jun protein expression in DU145 cells increases after
treatment with camptothecin. Protein extracts of untreated cells, and cells
treated with anti-Fas (200 ng ml–1), camptothecin (100 ng ml–1), or
camptothecin and anti-Fas, for 24 h, were run on a 10% (w/v) SDS-PAGE.
b-actin was also probed for to ensure equal protein loading
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MKP-1
-actin
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Figure 4 MKP-1 expression in DU145 cells. Expression was determined in
untreated cells, and in cells treated with anti-Fas (200 ng ml–1), camptothecin
(100 ng ml–1), or with both for 24 h. b-actin was probed to ensure equal
protein loading of the gel
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Figure 5 Inhibition of caspases has no effect on SAPK/JNK activation by
camptothecin and anti-Fas. SAPK/JNK activity was measured in untreated
(lane 2) DU145 cells, and cells treated with camptothecin (100 ng ml–1) and
anti-Fas (200 ng ml–1) in the presence of z-VAD (50 mM), for 12 h (lane 1).
As a control, b-actin was assessed in supernatant fractionstargeted to JNK1 and JNK2 to block the SAPK/JNK pathway.
Cells were electroporated in the presence of antisense (AS)
oligonucleotides, or non-sense (NS) oligonucleotides, as described
in Materials and Methods, and allowed to recover for 24 h.
The activity of SAPK/JNK was measured in untreated cells and in
cells treated with camptothecin and anti-Fas (8 h). Figure 6A
shows that concomitant treatment of DU145 cells with campto-
thecin, and anti-Fas strongly activates SAPK/JNK in cells treated
with NS, but not in cells treated with the AS, indicating that the AS
oligonucleotides were causing a specific inhibition of SAPK/JNK
activity. A slight induction of SAPK/JNK activity was noted in
untreated cells, suggesting that electroporation causes some stress
to the cells. This is, however, not comparable to the activation
induced by treatment with camptothecin and anti-Fas.
After electroporation in the presence of 2 mM of JNK1 AS and
2 mM of JNK2 AS, cells were allowed to recover for 24 h, and
were then treated with anti-Fas (200 ng ml–1), camptothecin
(100 ng ml–1), or both for 24 h. As a control, cells were electropo-
rated in the presence of NS, or in the absence of oligonucleotides.
Inhibition of SAPK/JNK by AS oligonucleotides dramatically
reduced the apoptosis of DU145 cells induced by concomitant
treatment with camptothecin and anti-Fas. Apoptosis levels were
comparable to those induced by treatment with camptothecin
alone (Figure 6B). Treatment of cells with NS oligonucleotides
had no significant effect on camptothecin sensitization of DU145
prostate cancer cells to anti-Fas-induced apoptotic cell death, thus
suggesting that inhibition of apoptosis is specific to SAPK/JNK
inhibition. These results strongly support a key role for
SAPK/JNK in Fas-signalling in DU145 prostate cancer cells.
DISCUSSION
Although there is still some controversy in the literature about the
relevance of SAPK/JNK activation in the cell death pathway(s)
induced by Fas, activation of Fas itself has been shown to activate
SAPK/JNK even when this activity is not essential for apoptosis
(Lenczowski et al, 1997). In this case, cells were sensitive to Fas
alone and did not require a secondary signal for sensitization.
DU145 cells express both Fas and FasL, but are resistant to
anti-Fas-mediated apoptosis, unless pretreated with sublethal
doses of a cytotoxic drug, such as camptothecin (Costa-Pereira and
Cotter, 1999). Here, we show that treatment of DU145 prostate
cancer cells with anti-Fas failed to activate SAPK/JNK.
Concomitant treatment of cells with camptothecin and anti-Fas,
however, strongly and persistently activated SAPK/JNK, which
correlated well with cell death. In addition, anisomycin, a strong
activator of SAPK/JNK, synergized with anti-Fas to the same
extent as camptothecin, suggesting that SAPK/JNK activation was
indeed required for DU145 cells to undergo anti-Fas-induced
apoptosis. Moreover, camptothecin, but not anti-Fas, induced
expression of c-Jun, indicating that camptothecin not only modu-
lates the SAPK/JNK cascade by mediating the phosphorylation
and activation of SAPK/JNK (which, in turn, will presumably
activate c-Jun), but also modulates the pathway at the protein
level by inducing c-Jun expression. MKP-1 expression levels have
been reported to be elevated in prostate cancer. MKP-1 protein
levels remained constant after treatment of cells with campto-
thecin, suggesting that modulation of SAPK/JNK activity by
camptothecin is independent of MKP-1. It remains possible,
however, that alterations of MKP-1 activity may be involved in
the modulation of SAPK/JNK.
We have previously shown that activated caspases were required
for this cytotoxicity (Costa-Pereira and Cotter, 1999). However,
inhibition of caspase activity by the pan-inhibitor z-VAD had no
effect on SAPK/JNK activation following concomitant treatment
of cells with camptothecin and anti-Fas, suggesting that
SAPK/JNK activation was not caspase-dependent. The results also
indicate that SAPK/JNK activation is not a secondary effect of the
death induced by camptothecin and anti-Fas, and that camp-
tothecin-induced activation of SAPK/JNK is thus an upstream and
early event, which is important for Fas signalling in these cells.
Antisense oligonucleotides targeted to JNK1 and JNK2
reversed camptothecin’s effect(s), indicating that the SAPK/JNK
cascade plays a critical role in Fas-mediated apoptotic cell death in
DU145 prostate cancer cells. These cells are resistant to apoptosis
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Figure 6 Inhibition of SAPK/JNK activity by antisense oligonucleotides
targeted to JNK1 and JNK2. (A) The activity of SAPK/JNK was assessed in
cells which had been electroporated in the presence of JNK AS (lanes 1 and
3), or in the presence of JNK NS (lanes 2 and 4). In order to activate
SAPK/JNK cells were treated with camptothecin (100 ng ml–1) and anti-Fas
(200 ng ml–1), for 8 h (lanes 3 and 4). As a control, b-actin was assessed in
supernatant fractions. (B) Inhibition of SAPK/JNK activity by JNK1 and JNK2
antisense oligonucleotides reverses camptothecin sensitization of DU145
cells to anti-Fas-induced apoptosis. Cells were electroporated in the absence
of oligonucleotides (n); or in the presence of SAPK/JNK As (n); or
SAPK/JNK NS ( ), and subsequently treated for 24 h with anti-Fas
(200 ng ml–1), camptothecin (100 ng ml–1), or both. Apoptosis levels were
assessed as described in Figure 1A. The data (from three independent
microscopic fields) represents mean apoptosis ± standard error of the mean
and the results shown are representative of three independent experimentsinduced by anti-Fas treatment, even at high concentrations (e.g.
1.5 mg ml–1, data not shown). The fact that anti-Fas antibodies fail
to induce apoptosis in DU145 cells and to activate SAPK/JNK,
and the fact that camptothecin, a cytotoxic drug which has been
shown to activate SAPK/JNK, sensitizes the cells to Fas-mediated
cytotoxicity, together with the AS data, strongly suggest that
SAPK/JNK plays an important role in Fas-signalling pathway(s) in
these cells.
Other groups have reported that cells which are sensitive to
apoptosis, or have seen sensitized to apoptosis, can activate stress
kinases downstream of caspases (Juo et al, 1998). MEKK1 has
been shown to be cleaved and activated by a caspase, which may
then be responsible for SAPK/JNK activation (Xu and Cobb,
1997). In our system we have evidence of this also, as in cells
which had been induced to undergo apoptosis (Fas and campto-
thecin), SAPK/JNK activation was higher than in cells which were
alive but had elevated SAPK/JNK activity due to the presence of
camptothecin alone. Our data, however, demonstrates that in Fas-
resistant cell line SAPK/JNK plays a more important role in the
upstream regulation of Fas sensitivity, as its activation was
required for sensitization to Fas, and was upstream of caspase
activation. Another report regarding Fas-insensitive cell lines also
indicated the presence of an inhibitor upstream of caspases
(Rokhlin et al, 1998). It is notable that the TRAIL/Apo-2 ligand
can also activate SAPK/JNK by both caspase-dependent and
-independent pathways (Muhlenbeck et al, 1998).
The nature by which SAPK/JNK sensitizes cells to Fas remains
to be established. Frost and colleagues (1999) have suggested that
drug-mediated sensitization to Fas killing may be due to alter-
ations in pre-existing proteins, and that this phenomena is indepen-
dent of de novo protein synthesis. Activation of a kinase such as
SAPK/JNK by cytotoxic drugs may lead to phosphorylation and
activation of activator proteins and/or inhibition of inhibitory
proteins, independently of Fas and of caspases, in parallel
signalling cascades. This would presumably release the inhibition
in Fas-mediated apoptosis signalling pathways.
Fas can activate at least two independent pathways: the Fas-
FADD-caspase 8 axis, which leads to a caspase cascade and apop-
tosis, and the more recently described Fas-Daax-ASK1 axis, which
leads to the activation of SAPK/JNK and/or p38MAPK cascades
(Chang et al, 1998). Chang and colleagues (1998) provide
evidence for a critical role of ASK1 in SAPK/JNK activation and
apoptosis induced by Fas binding of Daax, and suggest that the
Daax-ASK1 axis provides a mechanism for caspase-independent
activation of SAPK/JNK by Fas and other stimuli. Thus, the inhi-
bition in Fas signalling could also be at the level of Daax-ASK1.
Bcl-2 is often over-expressed in prostatic cancers (Krajewska
et al, 1996), and it is possible that these proteins play a role in the
loss of sensitivity to Fas-mediated apoptosis in the prostate.
Interestingly, it has recently been shown that overexpression of
SAPK/JNK antagonized the anti-apoptotic effect of Bcl-2,
presumably due to sustained activation of SAPK/JNK (Park et al,
1997). Pro-apoptotic Bcl-2 family members, such as Bax, can
antagonize the effects exerted by the anti-apoptotic members.
Indeed, it is believed that the ratios between these proteins are
important determinants of the cell’s fate following injury (Reed,
1997). Phosphorylation of Bcl-2 has been shown to inactivate its
anti-apoptotic function by displacing it from Bax, thereby altering
the ratios between these two proteins (Haldar et al, 1996).
Importantly, Maundrell and colleagues (1997) have shown that
Bcl-2 could be phosphorylated by SAPK/JNK, and Yamamoto
et al (1999) have more recently shown that Bcl-2 is phosphoryl-
ated by a cascade involving ASK1 which has also been implicated
in Fas signalling (Chang et al, 1998). Persistent activation of
SAPK/JNK by camptothecin may, therefore, induce apoptosis by
eliciting different, but complementary, cellular responses. It
remains possible that activation of SAPK/JNK by camptothecin
may induce, via c-Jun or other transcription factors, the transcrip-
tion of genes important for apoptosis. More likely, however, is the
possibility that SAPK/JNK may directly phosphorylate existing
proteins which regulate cell fate, such as Bcl-2, or Bcl-xL, or
indeed unidentified proteins.
Interestingly, MKK4/SEK1 has been identified as a candidate
tumour suppressor gene (Teng et al, 1997; Su et al, 1998) and more
recently as a candidate prostate cancer metastasis suppressor gene
encoded by human chromosome 17 (Yoshida et al, 1999). Loss of
tumour suppressor and/or metastasis suppressor genes are impor-
tant events in the progression towards a malignant phenotype. It is
tempting to speculate that, by activating SAPK/JNK, campto-
thecin is mimicking a cellular defence mechanism, which has been
lost during tumour progression.
We have characterized here a pathway which may enable
prostate cancer cells to escape immunological Fas-induced death.
Importantly, SAPK/JNK has been shown to act upstream in the
Fas-signalling pathway(s). If loss of sensitivity to Fas signalling is
shown to play a direct role in the progression of prostate cancer,
then restoring the cells’ susceptibility to Fas ligation will be of
obvious importance for future medical intervention in prostate
cancer patients. These results may, thus, provide us with clues for
a better understanding of prostate cancer progression, and for the
development of new strategies for the management and treatment
of the disease.
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